The need for axillary dissection in patients with positive axillary sentinel lymph nodes

Current Oncology Reports

Volumn 13, Issue 1, 2011, Pages 5-10

  Croshaw, Randal L ^a,b   Erb, Kathleen M ^a,b   Shapiro Wright, Hilary M ^c   Julian, Thomas B ^a,b,d  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b ALLEGHENY GENERAL HOSPITAL   (United States)

^c SSM Healthcare St Clare Hospital   (United States)

^d NSABP Foundation Inc   (United States)

Author keywords

Axillary dissection; Chemotherapy; Completion axillary dissection; Isolated tumor cells; Micrometastases; Micrometastasis; Neoadjuvant; Sentinel lymph node

Indexed keywords

TAMOXIFEN; TRASTUZUMAB;

ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HUMAN; ISOLATED TUMOR CELL; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHEDEMA; MICROMETASTASIS; OVERALL SURVIVAL; PROGNOSIS; SENTINEL LYMPH NODE; SENTINEL LYMPH NODE BIOPSY; SHOULDER DISEASE; SHOULDER PAIN; TUMOR CELL;

AXILLA; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; SENTINEL LYMPH NODE BIOPSY;

EID: 79551560924     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-010-0133-0     Document Type: Article

References (37)

1. B Fisher C Redmond ER Fisher, et al. 1985 Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation N Engl J Med 312 674 681 1:STN:280:DyaL2M7jslOitQ%3D%3D 10.1056/NEJM198503143121102 3883168
2. DN Krag JA Stewart TB Julian, et al. 2007 Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomized phase III trial Lancet Oncol 8 881 888 1:CAS:528: DC%2BD2sXhtFektbzM 10.1016/S1470-2045(07)70278-4 17851130 (Pubitemid 47488052)
3. JV Kiluk QP Ly AA Santillan, et al. 2010 Erratum to: Axillary recurrence rate following negative sentinel node biopsy for invasive breast cancer: long-term follow-up Ann Surg Oncol 17 552 557 10.1245/s10434-009-0800-2 19957043
4. U Veronesi V Galimberti G Paganelli, et al. 2009 Axillary metastases in breast cancer patients with negative sentinel nodes: a follow-up of 3548 cases Eur J Cancer 45 1381 1388 10.1016/j.ejca.2008.11.041 19128957
5. T Ashikaga DN Krag SR Land, et al. 2010 Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection J Surg Oncol 102 111 118 10.1002/jso.21535 20648579
6. Giuliano AE, McCall LM, Beitsch PD, et al.: ACOSOG Z0011: a randomized trial of axillary node dissection in women with clinical T1-2 N0 M0 breast cancer who have a positive sentinel node. J Clin Oncol 2010, 28(Suppl):abstr CRA506. This study reports on a large phase 3 trial to date revealing no benefit of axillary node dissection for patients with clinically node negative but pathologically positive sentinel nodes.
7. Martelli 2005 A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: Results after 5 years of follow-up Ann Surg 242 1 9 10.1097/01.sla.0000167759.15670.14 15973094 (Pubitemid 40917960)
8. AR Taras NA Hendrickson KA Lowe, et al. 2010 Recurrence rates in breast cancer patients with false-negative intraoperative evaluation of sentinel lymph nodes Am J Surg 199 625 628 10.1016/j.amjsurg.2010.01.009 20466106
9. H Takei M Kurosumi T Yoshida, et al. 2010 Axillary lymph node dissection can be avoided in women with breast cancer with intraoperative, false-negative sentinel lymph node biopsies Breast Cancer 17 9 16 10.1007/s12282-009-0154-4 19701679
10. KY Bilimoria DJ Bentrem NM Hansen, et al. 2009 Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer J Clin Oncol 27 2946 2953 10.1200/JCO.2008.19.5750 19364968
11. ER Fisher A Palekar H Rockette, et al. 1978 Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol No. 4) V. Significance of axillary nodal micro-and macrometastases Cancer 42 2032 2038 1:STN:280:DyaE1M%2FktlGmsw%3D%3D 10.1002/1097-0142(197810)42:4<2032::AID- CNCR2820420453>3.0.CO;2-O 361220 (Pubitemid 9055972)
12. GP Kuijt AC Voogd LV van de Poll-Franse, et al. 2005 The prognostic significance of axillary lymph-node micrometastases in breast cancer patients Eur J Surg Oncol 31 500 505 1:STN:280:DC%2BD2M3nvVOgtw%3D%3D 10.1016/j.ejso.2005.01.001 15922886 (Pubitemid 40724091)
13. J Reed M Rosman KM Verbanac, et al. 2009 Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study J Am Coll Surg 208 333 340 10.1016/j.jamcollsurg.2008.10.036 19317993 The rate of distant recurrence is reported at 4.9 years and reveals increased recurrence risk in patients with isolated tumor cells, micrometastases, and macrometastases in sentinel nodes
14. PT Truong M Lesperance KH Li, et al. 2010 Micrometastatic node-positive breast cancer: Long-term outcomes and identification of high-risk subsets in a large population-based series Ann Surg Oncol 17 2138 2146 10.1245/s10434-010- 0954-y 20151215 This study reports on a large number of patients with N0, N1mi, or N1 disease for 10 years revealing statistically significant prognostic information
15. DC Maibenco GW Dombi TY Kau, et al. 2006 Significance of micrometastases on the survival of women with T1 breast cancer Cancer 107 1234 1239 10.1002/cncr.22112 16900518 (Pubitemid 44452771)
16. SL Chen FM Hoehne AE Giuliano 2007 The prognostic significant of micrometastases in breast cancer: A SEER population-based analysis Ann Surg Oncol 14 3378 3384 10.1245/s10434-007-9513-6 17899293 (Pubitemid 350160103)
17. M De Boer JA Van Dijck P Bult, et al. 2010 Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases J Natl Cancer Inst 102 410 425 10.1093/jnci/djq008 20190185
18. NCCN Clinical Practice Guidelines in Clinical Oncology, Breast Cancer. Available at: http://www.nccn.org/professionals/physician-gls/PDF/breast.pdf. Accessed July 29, 2010.
19. American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer, September 12, 2005. Available at: http://www.asco.org/ASCOv2/Practice+%26+Guidelines/Guidelines/ Clinical+Practice+Guidelines/Breast+Cancer Accessed July 29, 2010.
20. J Rescigno J Zampell D Axelrod 2009 Patterns of axillary surgical care for breast cancer in the era of sentinel lymph node biopsy Ann Surg Oncol 16 687 696 10.1245/s10434-008-0195-5 19101768
21. N Wasif MA Maggard CY Ko AE Giuliano 2010 Underuse of axillary dissection for the management of sentinel node micrometastases in breast cancer Arch Surg 145 161 166 10.1001/archsurg.2009.269 20157084
22. N Wasif X Ye AE Giuliano 2009 Survey of ASCO members on management of sentinel node micrometastases in breast cancer: Variation in treatment recommendations according to specialty Ann Surg Oncol 16 2442 2449 10.1245/s10434-009-0549-7 19506955
23. CE Cox JV Kiluk AI Riker, et al. 2008 Significance of sentinel lymph node micrometastases in human breast cancer J Am Coll Surg 206 261 268 10.1016/j.jamcollsurg.2007.08.024 18222378 This study reports a difference in DFS and OS for patients with micrometastatic disease. However, it failed to show a benefit for axillary dissection in micrometastatic disease
24. M De Boer CHM Van Deurzen JAAM Van Dijck, et al. 2009 Micrometastasis or isolated tumor cells and the outcome of breast cancer N Engl J Med 361 653 663 10.1056/NEJMoa0904832 19675329 The DFS of patients with micrometastasis and isolated tumor cells based on adjuvant chemotherapy and the possible value of axillary dissection was discussed
25. Meretoja TJ, Vironen JH, Heikkila PS, Leidenius MH: Outcome of selected breast cancer patients with micrometastasis or isolated tumor cells in sentinel node biopsy and no completion axillary lymph node dissection. J Surg Oncol 2010, In press.
26. S Yegiyants LM Romero PI Haigh LA DiFronzo 2010 Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node Arch Surg 145 564 569 10.1001/archsurg.2010.84 20566977
27. I Langer U Guller CT Viehl, et al. 2009 Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study Ann Surg Oncol 16 3366 3374 10.1245/s10434-009-0660-9 19760047
28. S Pernas M Gil A Benitez, et al. 2010 Avoiding axillary treatment in sentinel lymph node micrometastases of breast cancer: a prospective analysis of axillary or distant recurrence Ann Surg Oncol 17 772 777 10.1245/s10434-009- 0804-y 20183912
29. N Klauber-DeMore DW Ollila DT Moore, et al. 2006 Size of residual lymph node metastasis after preoperative chemotherapy in locally advanced breast cancer patients is prognostic Ann Surg Oncol 13 685 691 10.1245/ASO.2006.03.010 16523367
30. M Sakakibara T Nagashima M Kadowaki, et al. 2009 Clinical significance of axillary microresiduals after neoadjuvant chemotherapy in breast cancer patients with cytologically proven metastasis Ann Surg Oncol 16 2470 2478 10.1245/s10434-009-0612-4 19588201 This article reported a statistical difference for DFS and OS in N1 patients who received neoadjuvant chemotherapy
31. HM Kuerer LA Newman AU Buzdar, et al. 1998 Residual metastatic axillary lymph nodes following preoperative chemotherapy predict disease-free survival in patients with locally advanced breast cancer Am J Surg 176 502 509 1:STN:280:DyaK1M7itl2luw%3D%3D 10.1016/S0002-9610(98)00253-0 9926779 (Pubitemid 29056639)
32. HM Kuerer AA Sahin KK Hunt, et al. 1999 Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with preoperative chemotherapy Ann Surg 230 72 78 1:STN:280:DyaK1MzisFKhtA%3D%3D 10.1097/00000658-199907000-00011 10400039 (Pubitemid 30190367)
33. HD Bear S Anderson A Brown, et al. 2003 The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J Clin Oncol 21 4165 4174 1:CAS:528: DC%2BD2cXpsVajtrg%3D 10.1200/JCO.2003.12.005 14559892 (Pubitemid 46606185)
34. ME Straver EJ Rutgers NS Russell, et al. 2009 Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer Eur J Cancer 45 2284 2292 1:STN:280:DC%2BD1MrntVahug%3D%3D 10.1016/j.ejca.2009.04.029 19464164
35. JM Classe V Bordes L Campion, et al. 2009 Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study J Clin Oncol 27 726 732 10.1200/JCO.2008.18.3228 19114697 This is a small prospective study evaluating the success of SNB after neoadjuvant chemotherapy in patients with N0 and N1 disease
36. V Ozmen ES Unal ME Muslumanoglu, et al. 2010 Axillary sentinel node biopsy after neoadjuvant chemotherapy Eur J Surg Oncol 36 23 29 1:STN:280:DC%2BC3c%2Fot1CktQ%3D%3D 19931375 This study provides evidence on the usefulness of SNB and intraoperative cytopathology to confirmed nodal disease and its prognostic value in patients following neoadjuvant chemotherapy
37. GF Schwartz JE Tannebaum AM Jernigan JP Palazzo 2010 Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast Cancer 116 1243 1251 10.1002/cncr.24887 20087958 This is a small retrospective study evaluating the authors' experience with SNB after neoadjuvant chemotherapy